相关实验视频

Updated: Sep 15, 2025

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

选择性氨酸载体利用是ARID1A突变卵巢癌的治疗脆弱性

Hao Nie¹, Liping Liao¹, Rafal J Zielinski¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Cancer research

|July 14, 2025

概括

癌症中的ARID1A突变通过改变载体,产生对氨酸的依赖. 抑制氨酸载体SLC38A2显示出作为单独或与免疫治疗一起的向治疗的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症新陈代谢癌症新陈代谢

背景情况:

在约20%的人类癌症中,SWI/SNF染色体重塑复杂子单元发生变化.
在卵巢透明细胞癌 (OCCC) 中,ARID1A突变很常见,这是一种治疗选择有限的癌症.

研究的目的:

研究ARID1A突变在癌症中的功能后果.
为了确定与ARID1A损失相关的潜在治疗漏洞.

主要方法:

对ARID1A对氨酸载体 (SLC38A2和SLC7A8) 的调节进行分析.
在ARID1A突变细胞中评估氨酸利用率.
在OCCC模型中对SLC38A2抑制的评估.
测试与免疫治疗 (CAR-T细胞和抗PD-L1) 的联合治疗.

主要成果:

通过抑制进口者SLC38A2和促进出口者SLC7A8.8.2,ARID1A突变导致细胞内氨酸水平的增加.
在ARID1A突变的OCCC细胞中,蛋白质合成和TCA循环对氨酸的依赖性增加.
抑制SLC38A2可以选择性地向ARID1A突变的OCCC.
抑制SLC38A2可以增强抗瘤免疫力,与免疫疗法产生协同作用.

结论:

在ARID1A突变中,对氨酸运输具有代谢脆弱性.
向氨酸运输代表了ARID1A突变癌症的潜在治疗策略.
氨酸运输抑制与免疫治疗的联合治疗需要进一步研究.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

ABC Transporters: Exporter

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...